By Fineline Cube Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical Products Administration (NMPA) has accepted for review the clinical filing of GenSci155, a Category 1 biologic product developed by its subsidiary Changchun GeneScience Pharmaceutical Inc. The long-acting, sustained-release recombinant human insulin-like growth factor-1 (IGF-1) analog is being developed for two distinct indications: prevention of bronchopulmonary dysplasia (BPD) in preterm infants and treatment of acute ischemic stroke (AIS).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Status | Clinical filing accepted for review |
| Product | GenSci155 (Category 1 biologic) – long-acting IGF-1 analog |
| Indications | Prevention of BPD in preterm infants; Treatment of acute ischemic stroke (AIS) |
| Developer | Changchun GeneScience Pharmaceutical Inc. (subsidiary of Changchun High-Tech) |
| Announcement Date | 7 May 2026 |
Drug Profile & Dual-Indication Strategy
Bronchopulmonary Dysplasia (BPD) Prevention
- Patient Population: Preterm infants at risk of developing chronic lung disease
- Administration: Flexible intravenous or subcutaneous injection options
- Advantage: More stable IGF-1 exposure profile demonstrated in preclinical studies
- Clinical Benefit: Supports different growth and development stages, potentially improving long-term treatment adherence
Acute Ischemic Stroke (AIS) Treatment
- Patient Population: Adults experiencing acute phase of ischemic stroke
- Administration: Rapid intravenous bolus delivery for immediate intervention
- Therapeutic Window: Enables early neuroprotective intervention during critical acute phase
- Clinical Benefit: Provides sustained neuroprotection before and after reperfusion therapy, maximizing clinical benefits within therapeutic time window and improving long-term functional outcomes
Innovation & Market Opportunity
| Therapeutic Area | Market Need | GenSci155 Differentiation |
|---|---|---|
| Neonatal Care | Limited options for BPD prevention; current treatments often inadequate | First long-acting IGF-1 analog with flexible administration routes tailored for preterm infant physiology |
| Stroke Therapy | Narrow therapeutic window; need for neuroprotective agents that complement reperfusion | Sustained neuroprotection that bridges pre- and post-reperfusion phases, potentially extending effective treatment window |
The dual-indication approach leverages the fundamental role of IGF-1 in both lung development and neuroprotection, representing a strategic application of a single molecular entity across distinct patient populations with high unmet medical needs.
Strategic Implications
- China Neonatal Health: With approximately 1 million preterm births annually in China, effective BPD prevention represents a significant public health opportunity.
- Stroke Burden: China faces one of the world’s highest stroke burdens, with over 2.4 million new stroke cases annually, creating substantial demand for innovative neuroprotective therapies.
- Biologics Leadership: As a Category 1 biologic, GenSci155 positions Changchun High-Tech at the forefront of China’s domestic biopharmaceutical innovation ecosystem.
- Global Potential: The novel long-acting IGF-1 analog platform could have applications beyond the initial indications, providing a foundation for future pipeline expansion.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory progress, clinical development, and market opportunities for GenSci155. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech